Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 27

1.

Thermal conditions within tree cavities in ponderosa pine (Pinus ponderosa) forests: potential implications for cavity users.

Vierling KT, Lorenz TJ, Cunningham P, Potterf K.

Int J Biometeorol. 2018 Apr;62(4):553-564. doi: 10.1007/s00484-017-1464-4. Epub 2017 Nov 5.

PMID:
29105010
2.

Marine Habitat Selection by Marbled Murrelets (Brachyramphus marmoratus) during the Breeding Season.

Lorenz TJ, Raphael MG, Bloxton TD Jr.

PLoS One. 2016 Sep 28;11(9):e0162670. doi: 10.1371/journal.pone.0162670. eCollection 2016.

3.

The role of wood hardness in limiting nest site selection in avian cavity excavators.

Lorenz TJ, Vierling KT, Johnson TR, Fischer PC.

Ecol Appl. 2015 Jun;25(4):1016-33.

PMID:
26465039
4.

The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study.

Cohen AT, Harrington R, Goldhaber SZ, Hull R, Gibson CM, Hernandez AF, Kitt MM, Lorenz TJ.

Am Heart J. 2014 Mar;167(3):335-41. doi: 10.1016/j.ahj.2013.11.006. Epub 2013 Dec 10.

5.

Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results.

Lopes RD, Williams JB, Mehta RH, Reyes EM, Hafley GE, Allen KB, Mack MJ, Peterson ED, Harrington RA, Gibson CM, Califf RM, Kouchoukos NT, Ferguson TB, Lorenz TJ, Alexander JH.

Am Heart J. 2012 Sep;164(3):379-386.e1. doi: 10.1016/j.ahj.2012.05.019.

6.

Addressing missing data in clinical trials.

van der Laan M, Lorenz TJ.

Ann Intern Med. 2011 Jul 19;155(2):135. doi: 10.7326/0003-4819-155-2-201107190-00016. No abstract available.

PMID:
21768593
7.

Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF).

Hernandez AF, O'Connor CM, Starling RC, Reist CJ, Armstrong PW, Dickstein K, Lorenz TJ, Gibler WB, Hasselblad V, Komajda M, Massie B, McMurray JJ, Nieminen M, Rouleau JL, Swedberg K, Califf RM.

Am Heart J. 2009 Feb;157(2):271-7. doi: 10.1016/j.ahj.2008.07.031. Epub 2008 Dec 19.

PMID:
19185633
8.

Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery.

Conte MS, Bandyk DF, Clowes AW, Moneta GL, Seely L, Lorenz TJ, Namini H, Hamdan AD, Roddy SP, Belkin M, Berceli SA, DeMasi RJ, Samson RH, Berman SS; PREVENT III Investigators.

J Vasc Surg. 2006 Apr;43(4):742-751; discussion 751.

9.

Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial.

Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB Jr, Lorenz TJ, Goyal A, Gibson M, Mack MJ, Gennevois D, Califf RM, Kouchoukos NT; PREVENT IV Investigators.

JAMA. 2005 Nov 16;294(19):2446-54.

PMID:
16287955
10.

Relation of early saphenous vein graft failure to outcomes following coronary artery bypass surgery.

Halabi AR, Alexander JH, Shaw LK, Lorenz TJ, Liao L, Kong DF, Milano CA, Harrington RA, Smith PK.

Am J Cardiol. 2005 Nov 1;96(9):1254-9. Epub 2005 Sep 6.

PMID:
16253593
11.

The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics.

Alexander JH, Ferguson TB Jr, Joseph DM, Mack MJ, Wolf RK, Gibson CM, Gennevois D, Lorenz TJ, Harrington RA, Peterson ED, Lee KL, Califf RM, Kouchoukos NT; PREVENT IV Investigators.

Am Heart J. 2005 Oct;150(4):643-9.

PMID:
16209958
12.

Design and rationale of the PREVENT III clinical trial: edifoligide for the prevention of infrainguinal vein graft failure.

Conte MS, Lorenz TJ, Bandyk DF, Clowes AW, Moneta GL, Seely BL.

Vasc Endovascular Surg. 2005 Jan-Feb;39(1):15-23.

13.

Ethics and equipoise: rationale for a placebo-controlled study design of platelet glycoprotein IIb/IIIa inhibition in coronary intervention.

Tcheng JE, Madan M, O'Shea JC, Cohen EA, Buller CE, Lincoff AM, Popma JJ, Teirstein PS, Kitt MM, Lorenz TJ, Greenberg S, Fost N, Califf RM.

J Interv Cardiol. 2003 Apr;16(2):97-105.

PMID:
12768912
14.

Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Lessons from the ESPRIT study.

Fernandes LS, Tcheng JE, O'Shea JC, Weiner B, Lorenz TJ, Pacchiana C, Berdan LG, Maresh KJ, Joseph D, Madan M, Mann T, Kilaru R, Hochman JS, Kleiman NS; ESPRIT investigators.

J Am Coll Cardiol. 2002 Sep 18;40(6):1085-91.

15.

Relationship of creatine kinase-myocardial band release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: an ESPRIT substudy.

Gibson CM, Murphy SA, Marble SJ, Cohen DJ, Cohen EA, Lui HK, Young J Jr, Kitt MM, Lorenz TJ, Tcheng JE.

Am Heart J. 2002 Jan;143(1):106-10.

PMID:
11773919
16.

Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study).

Tcheng JE, Talley JD, O'Shea JC, Gilchrist IC, Kleiman NS, Grines CL, Davidson CJ, Lincoff AM, Califf RM, Jennings LK, Kitt MM, Lorenz TJ.

Am J Cardiol. 2001 Nov 15;88(10):1097-102.

PMID:
11703951
17.

ESPRIT in context: pharmacology matters!

Tcheng JE, Strony J, Lorenz TJ, O'Shea JC.

Eur Heart J. 2001 Nov;22(21):1965-7. No abstract available.

PMID:
11603901
18.

Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention.

Gilchrist IC, O'Shea JC, Kosoglou T, Jennings LK, Lorenz TJ, Kitt MM, Kleiman NS, Talley D, Aguirre F, Davidson C, Runyon J, Tcheng JE.

Circulation. 2001 Jul 24;104(4):406-11.

PMID:
11468201
19.

Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial.

O'Shea JC, Hafley GE, Greenberg S, Hasselblad V, Lorenz TJ, Kitt MM, Strony J, Tcheng JE; ESPRIT Investigators (Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy trial).

JAMA. 2001 May 16;285(19):2468-73.

PMID:
11368699
20.

Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention.

O'shea JC, Madan M, Cantor WJ, Pacchiana CM, Greenberg S, Joseph DM, Kitt MM, Lorenz TJ, Tcheng JE.

Am Heart J. 2000 Dec;140(6):834-9.

PMID:
11099985

Supplemental Content

Loading ...
Support Center